Senseonics Holdings Gestione

Gestione criteri di controllo 2/4

Senseonics Holdings Il CEO è Tim Goodnow, nominato in Dec2015, e ha un mandato di 8.92 anni. la retribuzione annua totale è $ 3.59M, composta da 17.1% di stipendio e 82.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.84% delle azioni della società, per un valore di € 1.51M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 7.1 anni e 8.2 anni.

Informazioni chiave

Tim Goodnow

Amministratore delegato

US$3.6m

Compenso totale

Percentuale dello stipendio del CEO	17.1%
Mandato del CEO	8.9yrs
Proprietà del CEO	0.8%
Durata media del management	7.1yrs
Durata media del Consiglio di amministrazione	8.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Tim Goodnow rispetto agli utili di Senseonics Holdings?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$80m
Mar 31 2024	n/a	n/a	-US$81m
Dec 31 2023	US$4m	US$613k	-US$60m
Sep 30 2023	n/a	n/a	-US$32m
Jun 30 2023	n/a	n/a	-US$68m
Mar 31 2023	n/a	n/a	US$57m
Dec 31 2022	US$4m	US$586k	US$142m
Sep 30 2022	n/a	n/a	US$215m
Jun 30 2022	n/a	n/a	US$318m
Mar 31 2022	n/a	n/a	US$34m
Dec 31 2021	US$3m	US$569k	-US$302m
Sep 30 2021	n/a	n/a	-US$489m
Jun 30 2021	n/a	n/a	-US$555m
Mar 31 2021	n/a	n/a	-US$382m
Dec 31 2020	US$3m	US$552k	-US$175m
Sep 30 2020	n/a	n/a	-US$109m
Jun 30 2020	n/a	n/a	-US$105m
Mar 31 2020	n/a	n/a	-US$129m
Dec 31 2019	US$2m	US$536k	-US$116m
Sep 30 2019	n/a	n/a	-US$87m
Jun 30 2019	n/a	n/a	-US$100m
Mar 31 2019	n/a	n/a	-US$101m
Dec 31 2018	US$2m	US$536k	-US$94m
Sep 30 2018	n/a	n/a	-US$103m
Jun 30 2018	n/a	n/a	-US$88m
Mar 31 2018	n/a	n/a	-US$68m
Dec 31 2017	US$2m	US$520k	-US$59m

Compensazione vs Mercato: La retribuzione totale di Tim ($USD 3.59M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 808.68K ).

Compensazione vs guadagni: La retribuzione di Tim è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Tim Goodnow (62 yo)

8.9yrs

Mandato

US$3,589,760

Compensazione

Dr. Timothy T. Goodnow, also known as Tim, Ph D., has been the Chief Executive Officer, President and Director of Senseonics Holdings, Inc. since December 2015. Dr. Goodnow served as the Chief Executive Of...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Timothy Goodnow	President	8.9yrs	US$3.59m	0.84% € 1.5m
Mukul Jain	Chief Operating Officer	7.8yrs	US$1.56m	0.32% € 580.8k
Kenneth Horton	General Counsel & Corporate Development Advisor	7.1yrs	US$1.31m	0.21% € 373.4k
Francine Kaufman	Chief Medical Officer & Director	5.7yrs	Nessun dato	0.19% € 341.9k
Frederick Sullivan	CFO, Secretary & Treasurer	2.2yrs	Nessun dato	0.092% € 165.5k

7.1yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di 6L6 è esperto e expertise (durata media dell'incarico 7.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Timothy Goodnow	President	8.9yrs	US$3.59m	0.84% € 1.5m
Francine Kaufman	Chief Medical Officer & Director	5yrs	Nessun dato	0.19% € 341.9k
Douglas Roeder	Independent Non-Management Director	8.9yrs	US$174.75k	0.15% € 262.5k
Edward Fiorentino	Independent Non-Management Director	8.9yrs	US$169.00k	0.16% € 282.5k
Stephen DeFalco	Independent Chairman	8.9yrs	US$210.00k	0.29% € 516.5k
Steven Edelman	Independent Non-Management Director	8.2yrs	US$164.00k	0.14% € 259.4k
Douglas Prince	Independent Non-Management Director	8.9yrs	US$182.50k	0.12% € 213.7k
Brian Hansen	Director	less than a year	Nessun dato	Nessun dato
Anthony Raab	Independent Non-Management Director	4.1yrs	US$152.50k	0.080% € 143.2k
Sharon Larkin	Independent Non-Management Director	2.9yrs	US$159.00k	0.046% € 82.7k
Koichiro Sato	Director	1.5yrs	Nessun dato	Nessun dato

8.2yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 6L6 sono considerati esperti (durata media dell'incarico 8.2 anni).

Senseonics Holdings Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Senseonics Holdings, Inc., Annual General Meeting, May 22, 2024

Independent Non-Management Director recently bought €148k worth of stock

Senseonics Holdings, Inc. Elects Koichiro Sato as Directors

Senseonics Holdings, Inc. Announces CFO Transition

Senseonics Holdings, Inc., Annual General Meeting, May 26, 2022

President recently sold €1.0m worth of stock

Recent updates

New minor risk - Shareholder dilution

Senseonics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $16 million.

Senseonics Holdings, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Mercy Places First Commercial Eversense 365

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.033 loss per share (vs US$0.036 loss in 2Q 2023)

Senseonics Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Senseonics Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Senseonics Holdings, Inc. Reaffirms Revenue Guidance for the First Half and Provides Revenue Guidance for the Full Year of 2024

First quarter 2024 earnings released: US$0.031 loss per share (vs US$0.003 profit in 1Q 2023)

Senseonics Holdings, Inc. Announces Eversense CGM System Receives iCGM Designation by the U.S. Food and Drug Administration

Senseonics Holdings, Inc. to Report Q1, 2024 Results on May 13, 2024

Senseonics Holdings, Inc., Annual General Meeting, May 22, 2024

Full year 2023 earnings released: US$0.11 loss per share (vs US$0.30 profit in FY 2022)

Senseonics Holdings, Inc. Provides Revenue Guidance for the First Half of 2024

Senseonics Holdings, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023

Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023

Senseonics Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Senseonics Holdings, Inc. Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study

Independent Non-Management Director recently bought €148k worth of stock

New minor risk - Profitability

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.036 loss per share (vs US$0.23 profit in 2Q 2022)

Senseonics Holdings, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Sensonics Holdings, Inc. Announces New Clinical Data Demonstrating the Safety and Accuracy of Eversense Through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions

Senseonics Holdings, Inc. Elects Koichiro Sato as Directors

First quarter 2023 earnings released: EPS: US$0.003 (vs US$0.19 in 1Q 2022)

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023

Full year 2022 earnings released: EPS: US$0.30 (vs US$0.72 loss in FY 2021)

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.096 profit in 3Q 2021)

Senseonics Holdings, Inc. Revises Revenue Guidance for Full Year 2022

Senseonics Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Senseonics Holdings, Inc. Announces CFO Transition

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: US$0.23 (vs US$0.42 loss in 2Q 2021)

Investor sentiment improved over the past week

Senseonics Holdings Inc. Announces Positive Coverage Decision for Eversense E3 CGM from Anthem

Senseonics Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Investor sentiment improved over the past week

Senseonics Holdings, Inc. Announces European Approval of the Next-Generation Eversense E3 Continuous Glucose Monitoring System

Investor sentiment improved over the past week

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2022

First quarter 2022 earnings released: EPS: US$0.19 (vs US$0.69 loss in 1Q 2021)

Senseonics Holdings, Inc., Annual General Meeting, May 26, 2022

Senseonics Holdings, Inc. Announces the First Patient Implant of the Eversense E3 CGM System in the U.S

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Senseonics Holdings, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

President recently sold €1.0m worth of stock

Senseonics Announces FDA Approval of the Eversense® E3 Continuous Glucose Monitoring System for Use for Up to 6 months

Senseonics Holdings, Inc. Provides Revenue Guidance for the Fiscal Year 2021

Third quarter 2021 earnings released: EPS US$0.096 (vs US$0.099 loss in 3Q 2020)

Independent Non-Management Director recently sold €389k worth of stock

Second quarter 2021 earnings released: US$0.42 loss per share (vs US$0.033 loss in 2Q 2020)

Senseonics Holdings, Inc Announces the Results of the Promise Study Evaluating the Accuracy and Safety of the Next Generation Eversense CGM System for Up to 180 Days with Reduced Calibrations

Independent Non-Management Director Peter Klein has left the company

Senseonics Holdings, Inc. Reports Impairment Costs for the First Quarter Ended March 31, 2021

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.21 loss in 1Q 2020)

Senseonics Holdings, Inc. Provides Revenue Guidance for the Full Year 2021

Revenue beats expectations

Full year 2020 earnings released: US$0.72 loss per share (vs US$0.61 loss in FY 2019)

Senseonics Holdings, Inc. to Report Q4, 2020 Results on Mar 04, 2021

New 90-day high: €2.53

Senseonics Holdings, Inc. Announces a Positive Coverage Decision for Eversense CGM from EmblemHealth

New 90-day high: €1.44

Senseonics Holdings, Inc. announced that it has received $60.8 million in funding from Masters Special Situations, LLC, PHC Holdings Corporation, Masters Capital Management, L.L.C.

New 90-day high: €0.76

Senseonics Holdings, Inc. Increases Financial Guidance for the Fourth Quarter 2020

New 90-day high: €0.38